Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Allogene Therapeutics Q2 EPS $(0.53) Beats $(0.55) Estimate, Sales $44.00K

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.55) by 3.64 percent. This is unchanged from the same period last year. The company
byBenzinga Newsdesk
August 4, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.55) by 3.64 percent. This is unchanged from the same period last year. The company reported $44.00 thousand in sales this quarter.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts